Zymeworks Inc. Common Shares (ZYME): Price and Financial Metrics

Zymeworks Inc. Common Shares (ZYME): $9.58

-0.17 (-1.74%)

POWR Rating

Component Grades













Add ZYME to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where ZYME ranks best; there it ranks ahead of 78.05% of US stocks.
  • ZYME's strongest trending metric is Value; it's been moving up over the last 177 days.
  • ZYME ranks lowest in Stability; there it ranks in the 2nd percentile.

ZYME Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ZYME is 0.17 -- better than merely 15.75% of US stocks.
  • Of note is the ratio of ZYMEWORKS INC's sales and general administrative expense to its total operating expenses; merely 7.61% of US stocks have a lower such ratio.
  • ZYME's price/sales ratio is 20.57; that's higher than the P/S ratio of 94.03% of US stocks.
  • Stocks that are quantitatively similar to ZYME, based on their financial statements, market capitalization, and price volatility, are OPT, IMMP, GOVX, HIMX, and IVA.
  • Visit ZYME's SEC page to see the company's official filings. To visit the company's web site, go to www.zymeworks.com.

ZYME Valuation Summary

  • ZYME's price/earnings ratio is -2.8; this is 112.33% lower than that of the median Healthcare stock.
  • ZYME's price/sales ratio has moved down 8.8 over the prior 70 months.

Below are key valuation metrics over time for ZYME.

Stock Date P/S P/B P/E EV/EBIT
ZYME 2023-01-20 21.1 3.5 -2.8 -2.5
ZYME 2023-01-19 20.4 3.4 -2.7 -2.4
ZYME 2023-01-18 21.1 3.5 -2.8 -2.5
ZYME 2023-01-17 21.1 3.5 -2.8 -2.5
ZYME 2023-01-13 21.2 3.5 -2.8 -2.5
ZYME 2023-01-12 18.3 3.0 -2.4 -2.1

ZYME Growth Metrics

    The 4 year price growth rate now stands at 258.52%.
  • The 2 year revenue growth rate now stands at 7.97%.
  • Its 5 year net cashflow from operations growth rate is now at -44866.21%.
ZYME's revenue has moved down $506,000 over the prior 27 months.

The table below shows ZYME's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 29.859 -233.76 -224.242
2022-06-30 31.623 -211.532 -236.975
2022-03-31 27.952 -207.06 -239.878
2021-12-31 26.68 -192.451 -211.843
2021-09-30 22.49 -189.845 -210.584
2021-06-30 20.738 -155.115 -222.567

ZYME's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZYME has a Quality Grade of D, ranking ahead of 18.34% of graded US stocks.
  • ZYME's asset turnover comes in at 0.047 -- ranking 324th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ZYME's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.047 1 -1.423
2021-06-30 0.040 1 -1.267
2021-03-31 0.057 1 -0.902
2020-12-31 0.066 1 -0.661
2020-09-30 0.046 1 -0.832
2020-06-30 0.060 1 -0.772

ZYME Stock Price Chart Interactive Chart >

Price chart for ZYME

ZYME Price/Volume Stats

Current price $9.58 52-week high $10.80
Prev. close $9.75 52-week low $4.11
Day low $9.51 Volume 370,000
Day high $9.82 Avg. volume 978,211
50-day MA $8.02 Dividend yield N/A
200-day MA $6.58 Market Cap 603.57M

Zymeworks Inc. Common Shares (ZYME) Company Bio

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company was founded in 2003 and is based in Vancouver, BC.

ZYME Latest News Stream

Event/Time News Detail
Loading, please wait...

ZYME Latest Social Stream

Loading social stream, please wait...

View Full ZYME Social Stream

Latest ZYME News From Around the Web

Below are the latest news stories about ZYMEWORKS INC that investors may wish to consider to help them evaluate ZYME as an investment opportunity.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, January 25, 2023--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:

Yahoo | January 25, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off Thursday with an overview of the biggest pre-market stock movers traders will want to keep an eye on!

William White on InvestorPlace | January 19, 2023

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced tolerability and efficacy results, including the first overall survival (OS) data, from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).

Yahoo | January 19, 2023

Zymeworks nears one-year high after insider purchase

  • The shares of cancer-focused biopharma Zymeworks (NASDAQ:ZYMEadded ~13% on Friday to reach the highest level since late January 2021 after San Francisco-based biotech fund EcoR1 Capital, LLC raised its stake in the company.
  • According to an SEC filing on Thursday, EcoR1 has purchased ~1.0M Zymeworks (ZYME) shares this week for $7.65 – $8.87 apiece in Seeking Alpha | January 13, 2023

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023

VANCOUVER, British Columbia, January 04, 2023--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced updated key strategic priorities and provided updated financial guidance for the 2023 calendar year.

Yahoo | January 4, 2023

Read More 'ZYME' Stories Here

ZYME Price Returns

1-mo 21.88%
3-mo 28.94%
6-mo 56.03%
1-year 13.37%
3-year -78.36%
5-year -26.81%
YTD 21.88%
2022 -52.04%
2021 -65.32%
2020 3.96%
2019 209.67%
2018 93.41%

Continue Researching ZYME

Here are a few links from around the web to help you further your research on Zymeworks Inc's stock as an investment opportunity:

Zymeworks Inc (ZYME) Stock Price | Nasdaq
Zymeworks Inc (ZYME) Stock Quote, History and News - Yahoo Finance
Zymeworks Inc (ZYME) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9491 seconds.